Crossmark Global Holdings Inc. Sells 12,133 Shares of Qiagen (NYSE:QGEN)

Crossmark Global Holdings Inc. cut its stake in shares of Qiagen (NYSE:QGEN - Free Report) by 17.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 56,775 shares of the company's stock after selling 12,133 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Qiagen were worth $2,587,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Atria Investments Inc increased its position in shares of Qiagen by 6.0% in the 3rd quarter. Atria Investments Inc now owns 7,632 shares of the company's stock valued at $348,000 after acquiring an additional 433 shares during the period. US Bancorp DE increased its stake in Qiagen by 0.8% during the third quarter. US Bancorp DE now owns 69,122 shares of the company's stock worth $3,150,000 after acquiring an additional 580 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Qiagen by 39.9% in the third quarter. Assenagon Asset Management S.A. now owns 12,184 shares of the company's stock valued at $550,000 after purchasing an additional 3,474 shares during the period. Private Advisor Group LLC increased its stake in Qiagen by 8.0% in the third quarter. Private Advisor Group LLC now owns 6,251 shares of the company's stock valued at $285,000 after purchasing an additional 461 shares during the last quarter. Finally, Signaturefd LLC boosted its position in shares of Qiagen by 9.7% in the 3rd quarter. Signaturefd LLC now owns 8,038 shares of the company's stock valued at $366,000 after purchasing an additional 714 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Price Performance

NYSE QGEN traded down $0.60 on Wednesday, reaching $42.63. The company's stock had a trading volume of 803,279 shares, compared to its average volume of 1,166,503. The stock has a market cap of $9.73 billion, a PE ratio of 109.31, a PEG ratio of 3.29 and a beta of 0.41. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.46 and a current ratio of 2.17. The firm's 50 day moving average is $43.96 and its two-hundred day moving average is $43.77. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Robert W. Baird upped their price objective on Qiagen from $49.00 to $52.00 and gave the company an "outperform" rating in a research report on Friday, August 2nd. HSBC downgraded shares of Qiagen from a "buy" rating to a "hold" rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Finally, Hsbc Global Res upgraded shares of Qiagen to a "hold" rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Qiagen currently has an average rating of "Moderate Buy" and a consensus price target of $50.88.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.